The clinical use of granulocyte-colony stimulating factor

Shah, Jagruti; Welsh, Sarah J.

doi:10.12968/hmed.2014.75.sup2.c29

Cited by 6 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28][29][30] This therapy has several advantages over traditional treatments such as aspirin and thrombolytic agents because the therapy is less invasive, relatively safe, ethically acceptable, and has a wider therapeutic window. 31 Similarly, well-tolerated administration, feasible treatment regimen, and improved neurologic outcomes have been reported in the individual studies. 14,21 As to the clinical and functional outcomes, some studies 15,16,[20][21][22]27 found that the G-CSF did not show any progress in clinical outcomes at 90 days, although trends toward improvement were noted in change in the NIHSS 15 and BI scores.…”

Section: Summary Of Findingsmentioning

confidence: 84%

The Efficacy and Safety of Granulocyte Colony-Stimulating Factor for Patients with Stroke

Fan

Cai

et al. 2015

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

Section: Summary Of Findingsmentioning

confidence: 84%

The Efficacy and Safety of Granulocyte Colony-Stimulating Factor for Patients with Stroke

Fan

Cai

et al. 2015

Journal of Stroke and Cerebrovascular Diseases

View full text Add to dashboard Cite

“…G-CSF is a biologic response modifier, and its analog is widely employed in association with other antineoplastic drugs to revert the neutropenia resulting from chemotherapy. This association minimizes myelotoxicity, enhances neutrophil counts, and prevents delays in treatment [ 49 ].…”

Section: Cytokines and Pain In Human Breast Cancermentioning

confidence: 99%

Cytokines as Mediators of Pain‐Related Process in Breast Cancer

Panis

Pavanelli

2015

Mediators of Inflammation

View full text Add to dashboard Cite

Pain is a clinical sign of inflammation found in a wide variety of chronic pathologies, including cancer. The occurrence of pain in patients carrying breast tumors is reported and is associated with aspects concerning disease spreading, treatment, and surgical intervention. The persistence of pain in patients submitted to breast surgery is estimated in a range from 21% to 55% and may affect patients before and after surgery. Beyond the physical compression exerted by the metastatic mass expansion and tissue injury found in breast cancer, inflammatory components that are significantly produced by the host-tumor interaction can significantly contribute to the generation of pain. In this context, cytokines have been studied aiming to establish a cause-effect relationship in cancer pain-related syndromes, especially the proinflammatory ones. Few reports have investigated the relationship between pain and cytokines in women carrying advanced breast cancer. In this scenario, the present review analyzes the main cytokines produced in breast cancer and discusses the evidences from literature regarding its role in specific clinical features related with this pathology.

show abstract